These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 34477147)

  • 1. Prognostic significance of volume-based 18F-FDG PET/CT parameters and correlation with PD-L1 expression in patients with surgically resected lung adenocarcinoma.
    Wang D; Li Y; Chen X; Li P
    Medicine (Baltimore); 2021 Sep; 100(35):e27100. PubMed ID: 34477147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insight on the correlation of metabolic status on
    Wang Y; Zhao N; Wu Z; Pan N; Shen X; Liu T; Wei F; You J; Xu W; Ren X
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1127-1136. PubMed ID: 31502013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([
    Hughes DJ; Josephides E; O'Shea R; Manickavasagar T; Horst C; Hunter S; Tanière P; Nonaka D; Van Hemelrijck M; Spicer J; Goh V; Bille A; Karapanagiotou E; Cook GJR
    Eur Radiol; 2024 Feb; ():. PubMed ID: 38388716
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Wu X; Huang Y; Li Y; Wang Q; Wang H; Jiang L
    Ann Nucl Med; 2019 Sep; 33(9):647-656. PubMed ID: 31165974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The correlation between PD-L1 expression and metabolic parameters of
    Xu X; Li J; Yang Y; Sang S; Deng S
    Clin Imaging; 2022 Sep; 89():120-127. PubMed ID: 35797878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic Tumor Volume as Significant Predictor for Chemotherapy Containing PD-L1 Blocker in Extensive Stage Small Cell Lung Cancer.
    Hashimoto K; Kaira K; Imai H; Miura YU; Shiono A; Mouri A; Yamaguchi OU; Kobayashi K; Kagamu H; Kuji I
    Anticancer Res; 2024 Apr; 44(4):1541-1551. PubMed ID: 38537960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Volumetric Parameters Measured by Pretreatment 18F FDG PET/CT in Patients With Cutaneous Malignant Melanoma.
    Son SH; Kang SM; Jeong SY; Lee SW; Lee SJ; Lee J; Ahn BC
    Clin Nucl Med; 2016 Jun; 41(6):e266-73. PubMed ID: 27055144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of PD-L1 expression on tumor cell and tumor infiltrating immune cell with 18F-fluorodeoxyglucose uptake on PET/computed tomography in surgically resected pulmonary adenocarcinoma.
    Hu B; Xiao J; Xiu Y; Fu Z; Shi H; Cheng D
    Nucl Med Commun; 2020 Mar; 41(3):252-259. PubMed ID: 32068670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.
    Chung HW; Lee KY; Kim HJ; Kim WS; So Y
    J Cancer Res Clin Oncol; 2014 Jan; 140(1):89-98. PubMed ID: 24194352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 in Lung Adenocarcinoma: Insights into the Role of
    Cui Y; Li X; Du B; Diao Y; Li Y
    Cancer Manag Res; 2020; 12():6385-6395. PubMed ID: 32801879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
    Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Value of
    Vekens K; Everaert H; Neyns B; Ilsen B; Decoster L
    Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer.
    Wu X; Huang Y; Zhao Q; Wang L; Song X; Li Y; Jiang L
    EJNMMI Res; 2020 May; 10(1):51. PubMed ID: 32430866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer.
    Miccò M; Vargas HA; Burger IA; Kollmeier MA; Goldman DA; Park KJ; Abu-Rustum NR; Hricak H; Sala E
    Eur J Radiol; 2014 Jul; 83(7):1169-1176. PubMed ID: 24767630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The correlation of
    Qu YH; Long N; Ran C; Sun J
    Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on
    Takada K; Toyokawa G; Okamoto T; Baba S; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Honda H; Oda Y; Maehara Y
    Cancer Med; 2017 Nov; 6(11):2552-2561. PubMed ID: 28980429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of metabolic variables of [18F]FDG PET/CT in surgically resected stage I lung adenocarcinoma.
    Wang XY; Zhao YF; Liu Y; Yang YK; Wu N
    Medicine (Baltimore); 2017 Sep; 96(35):e7941. PubMed ID: 28858121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
    Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation study on 18F-FDG PET/CT metabolic characteristics of primary lesion with clinical stage in lung cancer.
    Hu WD; Wang HC; Wang YB; Cui LL; Chen XH
    Q J Nucl Med Mol Imaging; 2021 Jun; 65(2):172-177. PubMed ID: 30916535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of the prognostic value of PD-L1 expression and
    Jiang H; Zhang R; Jiang H; Zhang M; Guo W; Zhang J; Zhou X; Pan W; Zhao S; Li P
    J Cancer; 2020; 11(10):2864-2873. PubMed ID: 32226504
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.